Get the Stockscreener App
1.08
8.37%
-0.115
60 Degrees Pharmaceuticals Inc stock is traded at $1.08, with a volume of 86,241.
It is down -8.37% in the last 24 hours and down -27.48% over the past month.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.
See More
Previous Close:
$1.195
Open:
$1.19
24h Volume:
86,241
Relative Volume:
0.88
Market Cap:
$3.13M
Revenue:
$1.31M
Net Income/Loss:
$-7.56M
P/E Ratio:
-0.1049
EPS:
-10.2926
Net Cash Flow:
$-8.25M
1W Performance:
-3.10%
1M Performance:
-27.48%
6M Performance:
-65.89%
1Y Performance:
-79.26%
1-Day Range:
$1.02
$1.19
1-Week Range:
$1.02
$1.26
52-Week Range:
$1.02
$8.62
60 Degrees Pharmaceuticals Inc Stock (SXTP) Company Profile
Name
60 Degrees Pharmaceuticals Inc
Sector
Industry
Phone
202-327-5422
Address
1025 CONNECTICUT AVENUE NW, WASHINGTON
Compare SXTP vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SXTP
60 Degrees Pharmaceuticals Inc
|
1.0977 | 3.41M | 1.31M | -7.56M | -8.25M | -10.29 |
VRTX
Vertex Pharmaceuticals Inc
|
515.49 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.31 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
993.60 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
215.34 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.60 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
60 Degrees Pharmaceuticals Inc Stock (SXTP) Latest News
60 Degrees Pharmaceuticals (NASDAQ: SXTP) files to register 1.77M resale shares from warrant deal - Stock Titan
60 Degrees Q2 revenue jumps 106% to $208K; loss widens - scanx.trade
ARAKODA maker reports about $2.4M Q2 loss with about $208K revenue - Stock Titan
60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results - Yahoo Finance
60 Degrees Pharmaceuticals (SXTP) flags going concern risk as losses deepen - Stock Titan
60 Degrees Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
60 Degrees Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:SXTPW - TradingView
60 Degrees Pharmaceuticals Shareholders Approve Key Governance Actions - The Globe and Mail
60 Degrees Pharmaceuticals Inc (SXTP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
60 Degrees Pharmaceuticals (NASDAQ: SXTP) reports 2026 shareholder vote outcomes - Stock Titan
Lind Global Fund III (SXTP) discloses 5.45% stake with warrant conversion cap - Stock Titan
60 Degrees Pharmaceuticals Completes Private Placement to Raise Capital - TipRanks
60 Degrees Pharmaceuticals Raises $1.0 Million in Private Placement of Stock and Warrants - TradingView
60 Degrees Pharmaceuticals (NASDAQ: SXTP) raises $1M in warrant-backed private placement - Stock Titan
60 Degrees Pharmaceuticals issues Series A, Series B warrants exercisable at $1.49 in $1 million private placement - Bitget
60 Degrees Pharmaceuticals (SXTP) Slips 6.4% as Shares Test Key Support at $1.11Bear Pennant - dars.gov.et
60 Degrees Pharmaceuticals raises $1M in private placement By Investing.com - Investing.com Canada
60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules - GlobeNewswire
60 Degrees Pharmaceuticals, Inc. announced that it has received $0.999618 million in funding - marketscreener.com
60 Degrees Pharmaceuticals Announces Minimum Enrollment - GlobeNewswire
60 Degrees Pharmaceuticals hits babesiosis trial enrollment milestone - scanx.trade
60 Degrees Pharmaceuticals Inc (SXTP) Balance Sheet - TradingKey
60 Degrees Pharmaceuticals Inc - TradingKey
60 Degrees Pharmaceuticals Inc (SXTP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
60 Degrees Pharmaceuticals Inc (SXTP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
SXTP|60 Degrees Pharmaceuticals Inc|Price:1.140| - TradingKey
60 Degrees Pharmaceuticals Secures US Patent for Tafenoquine Lung Infection Treatment - scanx.trade
60 Degrees Pharmaceuticals Inc (SXTP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
60 Degrees Pharmaceuticals (SXTP) Slips 0.67% as Stock Hovers Near SupportCommon Gap - dars.gov.et
Enterprise value to revenue forward of 60 Degrees Pharmaceuticals, Inc. – NASDAQ:SXTP - TradingView
60 Degrees Pharmaceuticals Inc (SXTP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
60 Degrees Pharmaceuticals (SCTP) Proxy filing Summary - Quartr
60 Degrees Pharmaceuticals (SCTP) Registration Filing Summary - Quartr
60 Degrees Pharmaceuticals (SXTP) Edges Lower Near Support as Volume Remains SubduedWyckoff Accumulation - dars.gov.et
60 Degrees Pharmaceuticals: FDA-Approved Malaria & Babesiosis Treatments, Clinical Pipeline, and Commercial Growth (2026 Investor Update) – Minichart - Minichart
60 Degrees updates strategy for ARAKODA and profitability - TipRanks
60 Degrees Pharmaceuticals updates investor presentation; outlines Arakoda babesiosis trials, targets profitability - TradingView
Frontier tech research, news & data - MLQ.ai
60 Degrees Pharmaceuticals Inc. (SXTP) Q1 2026 Earnings: EPS Misses Estimates by Wide MarginGuidance Revision Trend - dars.gov.et
SXTP Q1 2026 Earnings: Wider-than-Expected Loss Sends Shares LowerEarnings Season Preview - po-news-eg.net
Enterprise value to EBITDA forward of 60 Degrees Pharmaceuticals, Inc. – NASDAQ:SXTP - TradingView
60 Degrees Pharmaceuticals, Inc. Warranton 60 Degrees Ph Financial Disclosures & SEC Filings - TradingView
Price to book forward of 60 Degrees Pharmaceuticals, Inc. – NASDAQ:SXTP - TradingView
60 Degrees Pharmaceuticals (NASDAQ: SXTP) Files 8-K Report Detailing Company Updates and Security Information - Minichart
Price to earnings forward of 60 Degrees Pharmaceuticals, Inc. – NASDAQ:SXTP - TradingView
Interim Trial Plan Finalized for Tafenoquine Babesiosis Study - TipRanks
60 Degrees Pharmaceuticals readies interim analysis plan for tafenoquine babesiosis trial - TradingView
60 Degrees Pharmaceuticals (SXTP) sets tafenoquine babesiosis interim analysis and sNDA path - Stock Titan
Price to earnings forward of 60 Degrees Pharmaceuticals, Inc. – NASDAQ:SXTPW - TradingView
60 Degrees Pharmaceuticals to Advance Castanospermine for Tick-Borne Diseases Through Florida State University Deal - Moomoo
60 Degrees Pharma gets option to pursue tick-borne disease drug - Stock Titan
60 Degrees Pharmaceuticals Inc Stock (SXTP) Financials Data
Revenue
Net Income
Cash Flow
EPS
60 Degrees Pharmaceuticals Inc Stock (SXTP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| DOW GEOFFREY S | President and CEO |
Dec 15 '25 |
Buy |
0.80 |
9,670 |
7,759 |
59,618 |
| DOW GEOFFREY S | President and CEO |
Dec 10 '25 |
Buy |
0.95 |
9,350 |
8,886 |
46,335 |
| DOW GEOFFREY S | President and CEO |
Dec 11 '25 |
Buy |
0.92 |
3,613 |
3,318 |
49,948 |
2.24%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):